These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 18849150)

  • 21. [Compliance in schizophrenia: predictive factors, therapeutical considerations and research implications].
    Misdrahi D; Llorca PM; Lançon C; Bayle FJ
    Encephale; 2002; 28(3 Pt 1):266-72. PubMed ID: 12091789
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prediction of medication noncompliance in outpatients with schizophrenia: 2-year follow-up study.
    Yamada K; Watanabe K; Nemoto N; Fujita H; Chikaraishi C; Yamauchi K; Yagi G; Asai M; Kanba S
    Psychiatry Res; 2006 Jan; 141(1):61-9. PubMed ID: 16318875
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relapse and therapeutic interventions in a 1-year observational cohort study of nonadherent outpatients with schizophrenia.
    Ciudad A; San L; Bernardo M; Olivares JM; Polavieja P; Valladares A; Gilaberte I
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Mar; 36(2):245-50. PubMed ID: 22056291
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the factors interfering with drug treatment compliance among Brazilian patients with schizophrenia.
    Rosa MA; Marcolin MA; Elkis H
    Braz J Psychiatry; 2005 Sep; 27(3):178-84. PubMed ID: 16224604
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How do socio-demographic and clinical factors interact with adherence attitude profiles in schizophrenia? A cluster-analytical approach.
    Beck EM; Cavelti M; Wirtz M; Kossowsky J; Vauth R
    Psychiatry Res; 2011 May; 187(1-2):55-61. PubMed ID: 21074860
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Persons suffering from schizophrenia and relapses].
    Passerieux C; Caroli F; Giraud-Baro E
    Encephale; 2009 Dec; 35(6):586-94. PubMed ID: 20004290
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predicting medication noncompliance after hospital discharge among patients with schizophrenia.
    Olfson M; Mechanic D; Hansell S; Boyer CA; Walkup J; Weiden PJ
    Psychiatr Serv; 2000 Feb; 51(2):216-22. PubMed ID: 10655006
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Psychopharmacology: insight and comorbid substance misuse and medication compliance among patients with schizophrenia.
    Kamali M; Kelly L; Gervin M; Browne S; Larkin C; O'Callaghan E
    Psychiatr Serv; 2001 Feb; 52(2):161-3, 166. PubMed ID: 11157110
    [No Abstract]   [Full Text] [Related]  

  • 29. Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia.
    Johnson DA
    J Clin Psychiatry; 1984 May; 45(5 Pt 2):13-21. PubMed ID: 6143743
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Which factors modify drug-compliance?].
    Albus M; Burkes S; Scherer J
    Psychiatr Prax; 1995 Nov; 22(6):228-30. PubMed ID: 8570752
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Subjective side effects of antipsychotics and medication adherence in people with schizophrenia.
    McCann TV; Clark E; Lu S
    J Adv Nurs; 2009 Mar; 65(3):534-43. PubMed ID: 19222651
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factors associated with antipsychotic medication adherence in community-based patients with schizophrenia in Hong Kong: a cross sectional study.
    Bressington D; Mui J; Gray R
    Int J Ment Health Nurs; 2013 Feb; 22(1):35-46. PubMed ID: 22738372
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). Current status of recommendations for treatment with an APAP].
    Buis C; Gourion D; Vaiva G
    Encephale; 2009 Jan; Suppl 3():S91-5. PubMed ID: 19268185
    [No Abstract]   [Full Text] [Related]  

  • 34. Choice of maintenance medication for schizophrenia.
    Davis JM; Chen N
    J Clin Psychiatry; 2003; 64 Suppl 16():24-33. PubMed ID: 14680416
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Schizophrenic patients' subjective reasons for compliance and noncompliance with neuroleptic treatment.
    Löffler W; Kilian R; Toumi M; Angermeyer MC
    Pharmacopsychiatry; 2003 May; 36(3):105-12. PubMed ID: 12806568
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [RÉALITÉ LT, a pharmacoepidemiological study of semiology and therapeutic strategy of patients with schizophrenia treated by antipsychotic loxapine in routine clinical practice].
    Cousin FR; Samuelian JC; Saoud M; Schmitt L; Vacheron MN; Vidailhet P; Augendre J; Walter M; Tonelli I; Pascal JC
    Encephale; 2012 Feb; 38(1):64-74. PubMed ID: 22381726
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Are we addressing the 'right stuff' to enhance adherence in schizophrenia? Understanding the role of insight and attitudes towards medication.
    Beck EM; Cavelti M; Kvrgic S; Kleim B; Vauth R
    Schizophr Res; 2011 Oct; 132(1):42-9. PubMed ID: 21820875
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rating of medication influences (ROMI) scale in schizophrenia.
    Weiden P; Rapkin B; Mott T; Zygmunt A; Goldman D; Horvitz-Lennon M; Frances A
    Schizophr Bull; 1994; 20(2):297-310. PubMed ID: 7916162
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Noncompliance in schizophrenia.
    Babiker IE
    Psychiatr Dev; 1986; 4(4):329-37. PubMed ID: 2883650
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sociodemographic and clinical factors associated with relapse in schizophrenia.
    Chabungbam G; Avasthi A; Sharan P
    Psychiatry Clin Neurosci; 2007 Dec; 61(6):587-93. PubMed ID: 18081617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.